Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review
- PMID: 36853384
- PMCID: PMC11798106
- DOI: 10.1007/s00432-023-04630-4
Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review
Abstract
Purpose: Clinical pharmacy can reduce drug-related iatrogenesis by improving the management of adverse effects of drugs, limiting drug-drug interactions, and improving patient adherence. Given the vulnerability of cancer patients and the toxicity of injectable anticancer drugs, clinical pharmacy service (CPS) could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on clinical pharmacy's impact on patients treated with intravenous anticancer drugs.
Methods: A comprehensive search was performed in the PubMed/Medline database from January 2000 to December 2021, associating the keywords: clinical pharmacy, pharmaceutical care, pharmacist, oncology, and chemotherapy. To be eligible for inclusion, studies have to report clinical pharmaceutical services for patients treated with intravenous chemotherapy with a clinical and/or economic impact.
Results: Forty-one studies met the selection criteria. Various CPS were reported: medication reconciliation, medication review, and pharmaceutical interview with patient. There was a lack of randomized study (n = 3; 7.3%). In one randomized controlled trial, pharmaceutical intervention significantly improved quality of life of patients receiving pharmaceutical care during injectable anticancer drugs courses. Economical results appear to show positive impact of clinical pharmacy with cost savings reported from 3112.87$ to 249 844€. Although most studies were non-comparative, they highlighted that clinical pharmacy tend to limit chemotherapy side effects and drug-related problems, improve quality of life and satisfaction of patients and healthcare professional, and a positive economic impact.
Conclusion: Clinical pharmacy can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.
Keywords: Cancer; Clinical pharmacist; Clinical pharmacy; Injectable anticancer drugs.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
On behalf of all authors, the corresponding author states that there is no conflict of interest.
References
-
- Ali K, Al-Quteimat O, Naseem R, Malhi SM, Wajdi M, Jahan N et al (2021) Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. J Oncol Pharm Pract 27(4):815–820 - PubMed
-
- Allison J, Fisher J, Souter C, Bennie M (2019) What patient assessment skills are required by pharmacists prescribing systemic anti-cancer therapy? A consensus study. J Oncol Pharm Pract 25(8):1933–1944 - PubMed
-
- Al-Taie A, Izzettin FV, Sancar M et al (2020) Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting. Eur J Cancer Care 29:e13261 - PubMed
-
- American College of Clinical Pharmacy (2008) The definition of clinical pharmacy. Pharmacotherapy 28(6):816–817 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
